← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,624	+266	+11%	$253B
2	2 Pfizer PFE $166B	2,244	+202	+10%	$154B
3	3 Merck MRK $364B	2,009	+85	+4%	$114B
4	4 AbbVie ABBV $501B	2,001	+203	+11%	$109B
5	5 Bristol-Myers Squibb BMY $121B	1,736	+94	+6%	$71.7B
6	6 Amgen AMGN $230B	1,735	+129	+8%	$99.8B
7	7 Gilead Sciences GILD $190B	1,576	+71	+5%	$73.2B
8	8 Novartis NVS $279B	1,007	+69	+7%	$21.1B
9	9 GSK GSK $95.9B	764	+22	+3%	$9.69B
10	10 Regeneron Pharmaceuticals REGN $80.1B	639	+33	+5%	$26.9B
11	11 AstraZeneca AZN $251B	504	+48	+11%	$13.4B
12	12 Incyte INCY $22.6B	503	+7	+1%	$18.8B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	323	+20	+7%	$7.32B
14	14 DELISTED Exact Sciences EXAS	318	+36	+13%	$5.21B
15	15 Exelixis EXEL $15.1B	302	+38	+14%	$7.27B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	298	+30	+11%	$7.87B
17	17 Myriad Genetics MYGN $397M	250	+30	+14%	$2.56B
18	CLVS 18 DELISTED Clovis Oncology, Inc. CLVS	247	-8	-3%	$3.5B
19	19 Opko Health OPK $1.02B	232	-2	-0.9%	$644M
20	20 Qiagen QGEN $9.41B	215	0	0%	$4.43B
21	21 Puma Biotechnology PBYI $527M	203	+32	+19%	$3.58B
22	22 DELISTED Immunogen Inc IMGN	200	+20	+11%	$666M
23	23 Halozyme HALO $13.3B	198	+32	+19%	$2.48B
24	24 Kyntra Bio KYNB $22.6M	187	+5	+3%	$2.66B
25	25 DELISTED Blueprint Medicines BPMC	170	+32	+23%	$3.23B